Salpharm Animal Health A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 0.0% 27.8% 2.4%  
Credit score (0-100)  0 0 0 1 63  
Credit rating  N/A N/A N/A B BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 1.3  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 -42.6 -10,364  
EBITDA  0.0 0.0 0.0 -42.6 -10,364  
EBIT  0.0 0.0 0.0 -42.6 -10,364  
Pre-tax profit (PTP)  0.0 0.0 0.0 -49.8 -10,336.8  
Net earnings  0.0 0.0 0.0 -49.8 -10,339.2  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 -49.8 -10,337  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 0.0 478 217,777  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 159,208  
Balance sheet total (assets)  0.0 0.0 0.0 487 383,541  

Net Debt  0.0 0.0 0.0 -487 146,257  
 
See the entire balance sheet

Volume 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 -42.6 -10,364  
Gross profit growth  0.0% 0.0% 0.0% 0.0% -24,249.5%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 0 487 383,541  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% 78,619.1%  
Added value  0.0 0.0 0.0 -42.6 -10,364.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 0.0 -1.0 -2.0  

Profitability 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 0.0% -8.7% -5.4%  
ROI %  0.0% 0.0% 0.0% -8.9% -5.5%  
ROE %  0.0% 0.0% 0.0% -10.4% -9.5%  

Solidity 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 0.0% 0.0% 98.1% 56.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 1,144.7% -1,411.1%  
Gearing %  0.0% 0.0% 0.0% 0.0% 73.1%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12
Quick Ratio  0.0 0.0 0.0 53.4 1.4  
Current Ratio  0.0 0.0 0.0 53.4 1.4  
Cash and cash equivalent  0.0 0.0 0.0 487.2 12,951.0  

Capital use efficiency 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 0.0 478.1 3,516.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
N/A
2022
N/A
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0